Home / Catalogue/ Growth recovery/ Tesamorelin

Growth recoveryMetabolicIn StockSubQ injection

Tesamorelin

Modified GHRH analogue · Trans-3-hexenoic acid conjugate · 44 amino acids

Half-life

~26min

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

2–8°C

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

GHRH analogue. FDA-approved specifically to reduce visceral (abdominal) fat in HIV-associated lipodystrophy. Targets belly fat specifically. Also improves cognitive function in some studies.

Mechanism of Action

Modified GHRH analog — stimulates pulsatile GH release. FDA-approved specifically for HIV-associated lipodystrophy (visceral fat reduction).

Body vs. External Supply

🟢 Secretagogue (stimulates natural)

Brand / Trade Names

Egrifta® / Egrifta SV® FDA-approved for HIV lipodystrophy Manufacturer: Theratechnologies

Typical Research Dosage

1-2mg daily SubQ. FDA dosing is 2mg/day.

Vial Duration Guide

2mg vial = 1-2 days. 10mg vial at 2mg/day = 5 days. 20mg = 10 days.

Recommended Vial Size

★ 10mg or 20mg vials At 2mg/day (FDA dose), 5mg = 2.5 days, 10mg = 5 days ✓, 20mg = 10 days ✓. 2mg = 1 day (impractical). Higher mg vials needed due to high daily dose.

Time to Effects

EARLY: 2-4 weeks FULL: 12-26 weeks Week 2-4: GH levels increase measurably on blood work (IGF-1). Week 4-8: Subtle reduction in visceral fat. May notice waistline changes. Week 12-26: Significant visceral fat reduction. Clinical trials showed meaningful reduction in trunk fat at 26 weeks. Cognitive improvements reported in some studies. Specifically targets belly fat — don't expect overall weight loss like GLP-1 agonists. Minimum commitment: 12 weeks.

Contraindications & Do Not Combine

• Do NOT combine with exogenous HGH • Do NOT combine with CJC-1295 or Sermorelin (all GHRH receptor agonists — pick one)

Common Side Effects

Injection site reactions (20-30%), joint pain (13%), pruritus (7%), peripheral edema, hyperglycaemia in pre-diabetic patients

Drug Interactions

Insulin/anti-diabetic drugs (may antagonize glucose control), cortisone, somatostatin analogs

Reversibility

🟢 Reversible — visceral fat returns within 3-6 months of stopping in HIV lipodystrophy studies

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Falutz et al. (2007) NEJM 357:2359-70 — HIV lipodystrophy visceral fat reduction • FDA Approved: Egrifta (2010) for HIV-associated lipodystrophy • Only FDA-approved GHRH analog currently on market • ClinicalTrials.gov: Multiple Phase 3 completed

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Refrigerate 2-8°C. Reconstituted: use immediately (within 20 min per product insert).

State	Condition	Duration
Lyophilised (sealed)	2–8°C	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

Tesamorelin discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$55.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~26 minutes (SubQ) \| ~38 minutes (IV)
Delivery	SubQ injection
Typical dose	1-2mg
Storage (lyoph.)	2–8°C
Storage (recon.)	4–6 weeks
Endogenous?	Secretagogue (stimulates natural)
Suppression	None (stimulates GH)
WADA	Prohibited (S2)
FDA status	Approved (Egrifta)